This invention is concerned with a novel polymorphic forms of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)4-( 5-(dimethyl-amino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)m orpholine hydrochloride which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic forms have advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)4-( 5-(dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)mo rpholine hydrochloride in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.

Этот вымысел связан с формами романа polymorphic составного хлоргидрата orpholine 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)4-(5$-(dimethyl-amino)methyl-1.2.3-triazol-4$-yl)methyl-3$-$$ET-5-(dimethyl-amino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)m-(4-fluorophenyl)m будет антагонистом приемного устройства tachykinin полезным в обработке или предохранении разладов центральной системы, воспалительных заболеваний, боли или мигрени, астмы, и emesis. The instant polymorphic формы имеют преимущества над другими знанными формами хлоргидрата rpholine 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)4-($$ET-5-(dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)mo in terms of термодинамические стабилность и пригодность для включения в фармацевтических образованиях.